Multi-Cancer Detection (MCD) blood tests are emerging technologies capable of detecting more than 50 different cancer types from a single blood sample. These tests aim to expand early detection beyond existing single-cancer screening programs by offering broader anatomic and histologic coverage in a single assay.
A recently enacted U.S. law establishes that Medicare will cover MCD tests when they receive FDA approval and demonstrate evidence of clinical benefit. That statutory guarantee of payment creates a foreseeable pathway for broad Medicare reimbursement if MCD products meet regulatory and evidentiary thresholds.
The manuscript provides estimates of the potential cost to Medicare if MCD tests are reimbursed. The analysis examines how total program cost varies under alternative assumptions about the per-test price, who among Medicare beneficiaries is eligible for screening, and the level of screening uptake in the eligible population. The study also quantifies follow-up diagnostic costs attributable to the screening program, treating downstream workup from false-positive results as avoidable costs of screening.
The authors used a modeling approach to estimate aggregate costs to Medicare under different input assumptions. Key model inputs and structural decisions described include the per-test cost of an MCD assay, definitions of the eligible Medicare population (for example, age or risk-based eligibility—precise eligibility criteria and population counts are provided in the manuscript), and assumed uptake or participation rates within that population.
The model separately accounts for immediate testing costs (the price paid by Medicare per screening test) and consequent diagnostic follow-up prompted by the screening results. Follow-up workup associated with positive screens that do not ultimately result in a cancer diagnosis—false positive-driven investigations—are considered avoidable harms and are tallied as additional program costs.
The manuscript presents multiple scenarios to show how total cost to Medicare changes with:
This scenario approach is intended to illustrate sensitivity of overall budget impact to policy choices (who is covered) and market factors (test pricing and real-world uptake).
A specific focus of the analysis is the cost of diagnostic follow-up that arises from screening results that do not correspond to confirmed cancer. These downstream costs may include imaging, specialist consultations, procedures, and other diagnostic services. The authors treat such costs as avoidable costs of screening because they are directly induced by the screening program and would not occur absent it.
The balance between test sensitivity and specificity, and the subsequent diagnostic pathway design, will determine how large these avoidable follow-up costs are relative to screening costs themselves.
The source summary reports that the manuscript provides estimates across the modeled scenarios but does not reproduce numeric results or detailed parameter values. Readers interested in specific dollar estimates, scenario tables, and sensitivity analyses should consult the full manuscript for the model inputs, assumptions, and quantitative outputs.
Because this work is presented as a medRxiv preprint, the analysis is preliminary and not peer reviewed at the time of posting (posted August 27, 2026). Limitations inherent to modeling studies apply: results depend on assumptions about test performance, pricing, eligibility criteria, and uptake, and the authors’ treatment of downstream diagnostic pathways. The precise limitations discussed in the manuscript are contained within the full text and should be reviewed there.
The analysis highlights that Medicare expenditures for MCD testing will depend jointly on test price, the size of the covered population, and real-world uptake. In addition, false positive-related follow-up can add avoidable costs to the program, meaning that test specificity and the structure of diagnostic follow-up pathways are important determinants of net budget impact. Policymakers and payers should consider cost scenarios together with evidence of clinical benefit when evaluating coverage and reimbursement approaches.
The authors report that all data produced in the present work are contained in the manuscript. Funding for the study is declared from Arnold Ventures. The authors declare no competing interests and affirm that ethical guidelines, participant consent, and applicable research reporting standards were followed. The work is posted as a medRxiv preprint (medRxiv 2026.08.24.26361257; doi: https://doi.org/10.64898/2026.08.24.26361257).